Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
enGene Holdings (ENGN)
NASDAQ:ENGN
Holding ENGN?
Track your performance easily
ENGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.42 - $18.40
Previous Close$8.25
Volume27.24K
Average Volume (3M)175.26K
Market Cap
$362.57M
Enterprise Value$131.96M
Total Cash (Recent Filing)$257.68M
Total Debt (Recent Filing)$24.86M
Price to Earnings (P/E)―
Beta-2.37
Next Earnings
Feb 03, 2025EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding44,215,577
10 Day Avg. Volume90,071
30 Day Avg. Volume175,260
Standard Deviation0.35
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.58
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.67
Forecast
1Y Price Target
$29.25Price Target Upside256.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
enGene Holdings News
PremiumCompany Announcements
enGene Holdings Secures $60 Million for Genetic Medicines
PremiumCompany Announcements
enGene Holdings Announces Key Executive Appointments
PremiumCompany Announcements
enGene Holdings Excels in Bladder Cancer Treatment TrialBulls Say, Bears Say
Bulls Say
Financial PerformanceSolid financial footing is established through February's $200M PIPE, indicating strong investor support and financial stability for ENGN.
Market PotentialENGN's market opportunities could extend to other mucosal cancers as additional candidates are developed.
Product EfficacyEG-70's early efficacy appears on par with virus-based drugs, with favorable safety and streamlined logistics that may encourage adoption in community practices.
Bears Say
Competitive PositionReduction in penetration in academic medical centers reflects likely competitive position vs CGON in these highly-resourced centers.
Market CompetitionThe current 6-month CR rate of 47% is lower than the competition.
Market DynamicsSome investors continue to believe that the NMIBC market is a winner-take-all environment, as they argue the data are not as strong as those for cretostimogene or TAR-200.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $4.42 and its highest was $18.40 in the past 12 months.
What is enGene Holdings’s market cap?
Currently, no data Available
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Feb 03, 2025 which is in 82 days.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Sep 10, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.375 by $0.055.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings does not currently pay dividends.
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -$0.41.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 44,215,576 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.375. Following the earnings report the stock price went up 3.077%.
Which hedge fund is a major shareholder of enGene Holdings?
Among the largest hedge funds holding enGene Holdings’s share is Omega Fund Management, LLC. It holds enGene Holdings’s shares valued at 10M.
---
enGene Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.25 (256.71% Upside)
$29.25 (256.71% Upside)
Blogger Sentiment
Bullish
ENGN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 998.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $8.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9999.00%
Trailing 12-Months
Company Description
enGene Holdings
Forbion European Acquisition Corp is a blank check company.
---
ENGN Stock 12 Month Forecast
Average Price Target
$29.25
▲(256.71% Upside)
Technical Analysis
Best Analysts Covering ENGN
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-8.53%
reiterated a buy rating 2 months ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -8.53% per trade.
---